BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 287 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $16,644,000 | +3.7% | 110,100 | 0.0% | 4.48% | +2.4% |
| Q2 2022 | $16,043,000 | +74.4% | 110,100 | +41.9% | 4.37% | +82.4% |
| Q1 2022 | $9,201,000 | +14.9% | 77,600 | +33.6% | 2.40% | +19.1% |
| Q4 2021 | $8,007,000 | -34.6% | 58,100 | -34.1% | 2.01% | -38.0% |
| Q3 2021 | $12,238,000 | +34.0% | 88,100 | -6.4% | 3.25% | +70.0% |
| Q2 2021 | $9,135,000 | +42.8% | 94,100 | +0.5% | 1.91% | +25.8% |
| Q1 2021 | $6,398,000 | -9.1% | 93,600 | +14.0% | 1.52% | -27.5% |
| Q4 2020 | $7,037,000 | +27.9% | 82,100 | -3.0% | 2.09% | +17.1% |
| Q3 2020 | $5,500,000 | -14.1% | 84,600 | -3.4% | 1.79% | -3.2% |
| Q2 2020 | $6,404,000 | +107.7% | 87,600 | -3.3% | 1.85% | +43.6% |
| Q1 2020 | $3,083,000 | -24.2% | 90,600 | +21.3% | 1.29% | -7.8% |
| Q4 2019 | $4,067,000 | +2.6% | 74,700 | -21.4% | 1.40% | -6.3% |
| Q3 2019 | $3,963,000 | -4.7% | 95,000 | 0.0% | 1.49% | -4.7% |
| Q2 2019 | $4,160,000 | +1.0% | 95,000 | +18.8% | 1.56% | -12.0% |
| Q1 2019 | $4,118,000 | +39.2% | 80,000 | 0.0% | 1.78% | +20.8% |
| Q4 2018 | $2,958,000 | +162.5% | 80,000 | +166.7% | 1.47% | +217.7% |
| Q3 2018 | $1,127,000 | +21.3% | 30,000 | +27.7% | 0.46% | +6.4% |
| Q2 2018 | $929,000 | – | 23,500 | – | 0.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 490,422 | $12,755,876 | 13.24% |
| FNY Investment Advisers, LLC | 30 | $0 | 0.00% |